| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
|
| ln Vitro |
In dose illumination concentrations, mesna (1-1000 μM) decreases H2O2, HOCl, and OH; in experiments without cells, the corresponding IC50 values were 32, 21, and 305 μM.
|
|---|---|
| ln Vivo |
Mesna (single intraperitoneal; 150 mg/kg) guards against brain stent injuries [1]. Mesna (200 mg/kg; single ip) reverses the glenoid function deficit caused by cisplatin [2]. Traumatic brain injury (TBI) was induced in adult male Wistar Albino rats weighing 250–350 g. The dose was 150 mg/kg, and the administration method was a single intraperitoneal injection. The results showed a decrease in tissue malondialdehyde levels. enhances superoxide dismutase and glutathione peroxidase activities. lowers nitric oxide, xanthine oxidase, and nitric oxide synthase levels. effectively shields brain cells from harm.
|
| Animal Protocol |
Animal/Disease Models: Adult male Wistar Albino rats (250-350 g) sustained traumatic brain injury (TBI) [1]
Doses: 150 mg/kg Route of Administration: Single intraperitoneal (ip) injection Experimental Results: diminished tissue malondialdehyde levels. Increases the activity of glutathione peroxidase and superoxide dismutase. Reduces levels of nitric oxide, nitric oxide synthase, and xanthine oxidase. Protects brain tissue well from damage. |
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Summary of Use during Lactation No information is available on the clinical use of mesna during breastfeeding. Because it is used with toxic drugs such as ifosfamide, the manufacturer recommends to not breastfeed during treatment and for 1 week after the last dose of mesna or ifosfamide. ◉ Effects in Breastfed Infants Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk Relevant published information was not found as of the revision date. |
| References |
|
| Additional Infomation |
Mesna is an organosulfonic acid.
Mesna is a sulfhydryl compound that is used to reduce the incidence of hemorrhagic cystitis associated with certain chemotherapeutic agents. Mesna is converted to a free thiol compound in the kidney, where it binds to and inactivates acrolein and other urotoxic metabolites of ifosfamide and cyclophosphamide, thereby reducing their toxic effects on the urinary tract during urinary excretion. (NCI04) A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. See also: Ifosfamide; mesna (component of). |
| Molecular Formula |
C2H5NAO3S2
|
|---|---|
| Molecular Weight |
164.18
|
| Exact Mass |
163.957
|
| CAS # |
19767-45-4
|
| Related CAS # |
3375-50-6 (parent cpd)
|
| PubChem CID |
23662354
|
| Appearance |
Off-white to gray solid powder
|
| Melting Point |
>240°C dec.
|
| LogP |
0.542
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
8
|
| Complexity |
123
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
XOGTZOOQQBDUSI-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C2H6O3S2.Na/c3-7(4,5)2-1-6;/h6H,1-2H2,(H,3,4,5);/q;+1/p-1
|
| Chemical Name |
sodium;2-sulfanylethanesulfonate
|
| Synonyms |
Filesna; Mesnum. US Mesnex. Foreign Ausobronc; mercaptoethane sulfonate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~1522.72 mM)
H2O : ≥ 50 mg/mL (~304.54 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (609.09 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.0909 mL | 30.4544 mL | 60.9088 mL | |
| 5 mM | 1.2182 mL | 6.0909 mL | 12.1818 mL | |
| 10 mM | 0.6091 mL | 3.0454 mL | 6.0909 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
